McDonald’s, the world’s largest fast food chain, is bracing itself for a new era in global eating habits, driven by the rising popularity of GLP-1 weight loss medications such as Ozempic, Wegovy, and Mounjaro. On February 18, 2026, company executives addressed the sweeping changes in consumer behavior during an earnings call, revealing that the chain is actively testing menu adjustments to accommodate a growing base of customers who are rethinking their food choices due to these medications.
According to statements made during the call and analysis by Simply Wall St, McDonald’s is not merely tweaking recipes or introducing a few new items. Instead, it’s embarking on a broad strategy to align its offerings with the needs and desires of a health-conscious clientele—many of whom are now using weight-loss pens that fundamentally alter appetite, impulse, and eating patterns. The company’s approach is multifaceted: it involves experimenting with higher protein items, reducing sugar and carbohydrates, introducing smaller portion sizes, and expanding its beverage and chicken product lines.
Chris Kempczinski, McDonald’s CEO, captured the essence of this transformation, stating that as the adoption of GLP-1 analog medications increases, “the way we consume also changes.” This shift, he explained, puts pressure on the traditional menu to evolve, as customers using these drugs are less likely to indulge in sugary drinks, desserts, and snacks, and more focused on foods rich in protein. “When adoption increases, the way we consume also changes,” Kempczinski emphasized during the call, as reported by Simply Wall St.
The ripple effects are far-reaching. Purchasing behavior is reorganizing itself from the drive-thru to the app and at the counter, as customers become more intentional and less impulsive in their choices. “It doesn’t mean the consumer becomes a different person, but that the purchase becomes less predictable: less ‘completing the order’ with extra items and more focus on something that seems substantial, with less carbohydrates and less sweetness,” noted Kempczinski. The company is seeking to understand how these shifts affect not just what’s on the plate, but also the broader experience of ordering and enjoying a meal at McDonald’s.
Jill McDonald, Vice President, pointed to existing higher-protein menu items—such as the Snack Wrap, sausage and biscuit sandwich, and McCrispy chicken strips—as examples of offerings that could gain new prominence. She suggested that the company may not need to reinvent its menu from scratch but could instead reposition these items to appeal to the changing tastes of customers using GLP-1 drugs. “The chain already has items perceived as higher in protein,” she said, hinting at a strategy that involves highlighting what’s already available rather than launching entirely new products.
Experts outside the company are speculating about what might be next. Mike Haracz, former corporate head of McDonald’s US office, predicted that consumers will notice “less carbohydrates and more protein,” with “fat” potentially becoming a marketing highlight to encourage purchase intent among GLP-1 users. Nutritionist Amy Goodson from Dallas-Fort Worth suggested that innovations could include grilled chicken strips or nuggets, cauliflower tortillas instead of traditional bread, and smaller burgers wrapped in lettuce—a format already seen at other chains like Shake Shack.
The underlying logic is pragmatic. As many doctors recommend that GLP-1 users consume more protein to help prevent loss of lean muscle mass, McDonald’s is responding to a goal that these consumers already bring to the table. The challenge is to make this transition without turning the menu into a medical prescription pad. The company is wary of making overt health promises and wants to avoid appearing overly promotional or clinical in its approach. Instead, the focus is on aligning with customer preferences in a subtle yet effective way.
One of the most significant consequences of these changing habits is the decline in impulse purchases of sugary drinks, desserts, and snacks—categories that have historically sustained McDonald’s margins and volume. As Kempczinski noted, “fewer sugary drinks” are being ordered, which means the company must find alternatives that satisfy customers’ new decision-making patterns without making the experience feel like a sacrifice. This could mean revising sizes, creating smaller versions, and adjusting how the app suggests add-ons, all in an effort to maintain relevance within a more selective purchase process.
Meanwhile, the company’s global ambitions remain undiminished. McDonald’s is planning to open approximately 2,600 new restaurants in 2026, expanding its footprint even as it experiments with new product platforms and portion formats. The company’s stock was trading around $327.62 at the time of the announcement, with strong returns over the past month, year, and five-year period—demonstrating that these changes are being made from a position of financial strength, not necessity.
For investors, the stakes are high. The big question, as outlined by Simply Wall St, is whether these menu shifts will simply help McDonald’s defend its existing guest counts as people eat fewer calories, or if they’ll allow the brand to win market share from rivals like Starbucks, Yum! Brands, and Restaurant Brands International by creating new occasions—especially in beverages. The expansion of the McCafé line, for example, targets a large global category that can support repeat visits and help McDonald’s compete more directly with coffee and drink-led peers.
However, there are risks. If GLP-1 driven calorie reductions lead to smaller order sizes and less frequent visits, and if new high-protein and portion-controlled options fail to engage higher-income and health-focused customers, the company could face pressure on traffic and average check size. Moreover, rolling out new formats and products across thousands of restaurants introduces operational complexities that could strain franchisees and impact margins.
Despite these challenges, McDonald’s management appears confident. The company is leaning into protein, portion control, and a broader beverage and chicken range, all while maintaining a wide menu to serve both traditional and emerging customer segments. The internal project to adapt the menu is set to begin testing in 2026, but no official new items have been announced yet.
As the fast food giant navigates this “new normal,” it’s clear that the most significant changes may not be in the food itself, but in how options are suggested, grouped, and communicated to an audience that now chooses with more intention and less improvisation. Whether this adaptation becomes a new chapter in McDonald’s storied menu history or simply a course correction for a specific, influential audience remains to be seen. But one thing is certain: the next time you step up to a McDonald’s counter, the choices you see—and the ones you make—may look very different from those of just a few years ago.